-
EP4029517
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4029517
| EP4029517 - COMBINATIONAL USES OF NITROXOLINE AND ITS ANALOGUES WITH CHEMOTHERAPIES AND IMMUNOTHERAPIES IN THE TREATMENT OF CANCERS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 11.11.2022 Database last updated on 02.09.2024 | |
| Former | The application has been published Status updated on 17.06.2022 | Most recent event Tooltip | 28.03.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Jiangsu Yahong Meditech Co., Ltd. Suite 1009, Phase II Building D China Medical City No.1 Yaocheng Avenue Taizhou, Jiangsu 225316 / CN | [2022/29] | Inventor(s) | 01 /
PAN, Ke Shanghai, 200126 / CN | 02 /
HUANG, Peng Okayama, 700-8558 / JP | 03 /
LI, Qiang Shanghai, 200120 / CN | [2022/29] | Representative(s) | LBP Lemcke, Brommer & Partner Patentanwälte mbB Siegfried-Kühn-Straße 4 76135 Karlsruhe / DE | [N/P] |
| Former [2022/29] | Lemcke, Brommer & Partner Patentanwälte Partnerschaft mbB Siegfried-Kühn-Straße 4 76135 Karlsruhe / DE | Application number, filing date | 22157650.7 | 31.03.2017 | [2022/29] | Priority number, date | US201662315774P | 31.03.2016 Original published format: US 201662315774 P | [2022/29] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP4029517 | Date: | 20.07.2022 | Language: | EN | [2022/29] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 21.06.2022 | Classification | IPC: | A61K39/395, A61P35/00, A61P35/04, C07K16/28, C07K16/30 | [2022/29] | CPC: |
C07K16/2818 (EP,KR,US);
A61K39/3955 (EP,KR,US);
A61K31/47 (KR,US);
A61K31/282 (US);
A61K31/337 (US);
A61K31/407 (US);
A61K31/704 (US);
A61K33/243 (US);
A61K39/04 (US);
A61K45/06 (KR);
A61K9/0019 (US);
A61K9/0053 (US);
A61P35/00 (EP,KR,US);
A61K2039/505 (EP,KR,US);
A61K2039/54 (EP,KR,US);
| C-Set: |
A61K39/3955, A61K2300/00 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/50] |
| Former [2022/29] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | KOMBINIERTE VERWENDUNGEN VON NITROXOLIN UND DESSEN ANALOGA MIT CHEMOTHERAPIEN UND IMMUNTHERAPIEN BEI DER BEHANDLUNG VON KREBS | [2022/29] | English: | COMBINATIONAL USES OF NITROXOLINE AND ITS ANALOGUES WITH CHEMOTHERAPIES AND IMMUNOTHERAPIES IN THE TREATMENT OF CANCERS | [2022/29] | French: | UTILISATIONS COMBINÉE DE NITROXOLINE ET DE SES ANALOGUES AVEC DES CHIMIOTHÉRAPIES ET DES IMMUNOTHÉRAPIES DANS LE TRAITEMENT DE CANCERS | [2022/29] | Examination procedure | 07.11.2022 | Amendment by applicant (claims and/or description) | 07.11.2022 | Examination requested [2022/50] | 07.11.2022 | Date on which the examining division has become responsible | Parent application(s) Tooltip | EP17776779.5 / EP3436071 | Fees paid | Renewal fee | 21.02.2022 | Renewal fee patent year 03 | 21.02.2022 | Renewal fee patent year 04 | 21.02.2022 | Renewal fee patent year 05 | 11.03.2022 | Renewal fee patent year 06 | 23.03.2023 | Renewal fee patent year 07 | 27.03.2024 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]US8729097 (LIU JUN O [US], et al) [Y] 1-8 * column 29, line 30 - line 50; claims 1, 6,7 *; | [AD] - Joong Sup Shim ET AL, "Effect of Nitroxoline on Angiogenesis and Growth of Human Bladder Cancer", Journal of the National Cancer Institute, United States, doi:10.1093/jnci/djq457, (20101215), pages 1855 - 1873, URL: https://academic.oup.com/jnci/article-pdf/102/24/1855/17310783/djq457.pdf, XP055633839 [AD] 1-8 * figures 7,8 * DOI: http://dx.doi.org/10.1093/jnci/djq457 | [Y] - MINORU HORINAGA, "Enhanced antitumor effect of combination intravesical mitomycin C and bacillus Calmette-Guerin therapy in an orthotopic bladder cancer model", ONCOLOGY LETTERS, (20101123), doi:10.3892/ol.2010.217, ISSN 1792-1074, XP055190481 [Y] 1-8 * table 5 * * abstract * DOI: http://dx.doi.org/10.3892/ol.2010.217 | [T] - Anonymous, "Abstract 2037: Oral nitroxoline in combination with intravesical bacille calmette-guerin (BCG) shows synergistic antitumor efficacy in mouse bladder cancer orthotopic xenograft | Cancer Research", (20170701), URL: https://cancerres.aacrjournals.org/content/77/13_Supplement/2037, (20200325), XP055679739 [T] * the whole document * | by applicant | - PELLETIER CPROGNON PBOURLIOUX P, "Roles of divalent cations and pH in mechanism of action of nitroxoline against Escherichia coli strains", Antimicrob Agents Chemother., (19950000), vol. 39, no. 3, doi:10.1128/AAC.39.3.707, pages 707 - 13, XP055072467 DOI: http://dx.doi.org/10.1128/AAC.39.3.707 | - FRASER RSCREANOR J., "The mechanism of inhibition of ribonucleic acid synthesis by 8-hydroxyquinoline and the antibiotic lomofungin", Biochem J., (19750000), vol. 147, no. 3, pages 401 - 10 | - ADLARD PA, "Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial A-beta", Neuron, (20080000), vol. 59, no. 1, pages 43 - 55 | - SHIM JS et al., "Effect of nitroxoline on angiogenesis and growth of human bladder cancer", J Natl Cancer Inst., (20100000), vol. 102, no. 24, doi:10.1093/jnci/djq457, pages 1855 - 73, XP055633839 DOI: http://dx.doi.org/10.1093/jnci/djq457 | - CHANG WL et al., "Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation", Oncotarget, (20150000), vol. 6, no. 37, pages 39806 - 20 | - JIANG H. et al., "Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline", Cancer Letters, (20110000), vol. 312, doi:10.1016/j.canlet.2011.06.032, pages 11 - 17, XP028304198 DOI: http://dx.doi.org/10.1016/j.canlet.2011.06.032 | - DING WQLIU BVAUGHT JLYAMAUCHI HLIND SE, "Anticancer activity of the antibiotic clioquinol", Cancer Res, (20050000), vol. 65, doi:10.1158/0008-5472.CAN-04-4385, pages 3389 - 95, XP002371610 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-04-4385 | - WHITESIDE TL, "Inhibiting the Inhibitors: Evaluating Agents Targeting Cancer Immunosuppression", Expert OpinBiolTher., (20100000), vol. 10, no. 7, doi:10.1517/14712598.2010.482207, pages 1019 - 1035, XP055654492 DOI: http://dx.doi.org/10.1517/14712598.2010.482207 | - FUGE OVASDEV NALLCHORNE PGREEN JS, "Immunotherapy for bladder cancer", Res Rep Urol., (20150000), vol. 7, pages 65 - 79 | - HUANG PMA CXU PGUO KXU ALIU C, "Efficacy of intravesical Bacillus Calmette-Guerin therapy against tumor immune escape in an orthotopic model of bladder cancer", ExpTherMed., (20150000), vol. 9, no. 1, pages 162 - 166 | - PARDOLL DM, "The blockade of immune checkpoints in cancer immunotherapy", Nat Rev Cancer., (20120000), vol. 12, no. 4, doi:10.1038/nrc3239, pages 252 - 64, XP037114946 DOI: http://dx.doi.org/10.1038/nrc3239 | - KRUMMEL MFALLISON JP, "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation", J Exp Med., (19950000), vol. 182, no. 2, doi:10.1084/jem.182.2.459, pages 459 - 65, XP001031165 DOI: http://dx.doi.org/10.1084/jem.182.2.459 | - HAMID OROBERT CDAUD AHODI FSHWU WJKEFFORD R et al., "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma", N Engl J Med., (20130000), vol. 369, no. 2, doi:10.1056/NEJMoa1305133, pages 134 - 44, XP055182016 DOI: http://dx.doi.org/10.1056/NEJMoa1305133 | - FREEMAN GJLONG AJIWAI Y et al., "Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation", J Exp Med., (20000000), vol. 192, doi:10.1084/jem.192.7.1027, pages 1027 - 1034, XP002942545 DOI: http://dx.doi.org/10.1084/jem.192.7.1027 | - HAWKES EAGRIGG ACHONG G, "Programmed cell death-1 inhibition in lymphoma", Lancet Oncol., (20150000), vol. 16, no. 5, doi:10.1016/S1470-2045(15)70103-8, pages e234 - 45, XP029586814 DOI: http://dx.doi.org/10.1016/S1470-2045(15)70103-8 | - LIU XSHIN NKOBLISH HK, "Selective inhibition of IDOl effectively regulates mediators of antitumor immunity", Blood, (20100000), vol. 115, doi:10.1182/blood-2009-09-246124, pages 3520 - 3530, XP055054663 DOI: http://dx.doi.org/10.1182/blood-2009-09-246124 | - OPITZ CALITZENBURGER UMOPITZ U et al., "The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDOl in human cancer cells", PloS One, (20110000), vol. 6, page 19823 | - MULLER AJPRENDERGAST GC, "Marrying immunotherapy with chemotherapy: why say IDO?", Cancer Res., (20050000), vol. 65, doi:10.1158/0008-5472.CAN-05-2213, pages 8065 - 8068, XP055049382 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-05-2213 | - TING-CHAO CHOU, "Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies", Pharmacol Rev, (20060000), vol. 58, doi:10.1124/pr.58.3.10, pages 621 - 681, XP055151376 DOI: http://dx.doi.org/10.1124/pr.58.3.10 | - YAN HZHANG BLI SZHAO Q, "A formal model for analyzing drug combination effects and its application in TNF-alpha-induced NFkappaB pathway", BMC Syst Biol., (20100000), vol. 4, page 50 | WO2014US30532 |